Maria Isabel Chiu

US Patent:

6464974, Oct 15, 2002

Filed:

Jan 23, 1998

Appl. No.:

09/012504

Inventors:

Vivian Berlin - Dunstable MA
Maria Isabel Chiu - Boston MA
Guillaume Cottarel - West Roxbury MA
Veronique Damagnez - Cambridge MA

Assignee:

Ariad Pharmaceuticals - Cambridge MA

International Classification:

C07K 1600

US Classification:

4241391, 4241461, 530350, 5303879, 53038826

Abstract:

The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes and provides, e. g. , isolated polypeptides, nucleic acids encoding such, antibodies, screening methods, and diagnostic and therepeutic methods.

US Patent:

6509152, Jan 21, 2003

Filed:

Jan 23, 1998

Appl. No.:

09/012399

Inventors:

Vivian Berlin - Dunstable MA
Maria Isabel Chiu - Boston MA
Guillaume Cottarel - West Roxbury MA
Veronique Damagnez - Cambridge MA

Assignee:

Ariad Gene Therapeutics, Inc. - Cambridge MA

International Classification:

C12Q 168

US Classification:

435 6, 435 15, 435194, 536 232, 536 234, 536 241

Abstract:

The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.

US Patent:

7556796, Jul 7, 2009

Filed:

Apr 5, 2006

Appl. No.:

11/398171

Inventors:

Murray Robinson - Boston MA, US
Ronan O'Hagan - Brookline MA, US
Karuppiah Kannan - Cambridge MA, US
Ti Cai - Andover MA, US
Maria Isabel Chiu - Newton Centre MA, US
Lorena Lerner - Newton Centre MA, US
Jie Lin - West Roxbury MA, US
Yinghui Zhou - Belmont MA, US

Assignee:

AVEO Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 49/00
A61K 35/12

US Classification:

424 91, 424520, 424573

Abstract:

A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene, thereby restoring tumorigenicity without expression of the inducible recombinant oncogene. Also disclosed is a method of testing a compound for anti-tumor effects. The method includes producing tumorigenic mouse cells the tumorigenicity depends on expression of a recombinant gene of interest, implanting the cells in mice and obtaining tumors from the implanted cells, administering test compounds to the mice, and determining anti-tumor effects, if any, of the compounds.

US Patent:

20050059803, Mar 17, 2005

Filed:

Jun 24, 2004

Appl. No.:

10/877320

Inventors:

Vivian Berlin - Arlington MA, US
Maria Chiu - Boston MA, US
Guillaume Cottarel - West Roxbury MA, US
Veronique Damagnez - Cambridge MA, US

Assignee:

ARIAD Gene Therapeutics, Inc. - Cambridge MA

International Classification:

C07K014/74

US Classification:

530350000

Abstract:

The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.

US Patent:

20110065898, Mar 17, 2011

Filed:

Nov 25, 2009

Appl. No.:

12/625940

Inventors:

Vivian Berlin - Arlington MA, US
Maria Isabel Chiu - Boston MA, US
Guillaume Cottarel - West Roxbury MA, US
Veronique Damagnez - Cambridge MA, US

Assignee:

ARIAD Gene Therapeutics, Inc. - Cambridge MA

International Classification:

C07K 14/00
C07H 21/04

US Classification:

530350, 536 2431, 536 2433

Abstract:

The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.

US Patent:

20120302572, Nov 29, 2012

Filed:

Apr 25, 2012

Appl. No.:

13/455972

Inventors:

Julie Kan - San Diego CA, US
Stuart Thomson - Port Washington NY, US
Gretchen M. Argast - Farmingdale NY, US
Matthew E. O'Connor - Massapequa Park NY, US
Murray Robinson - Boston MA, US
Bin Feng - North Reading MA, US
Joerg Heyer - Newton MA, US
Maria I. Chiu - Newton Centre MA, US
Richard Nicoletti - South Borough MA, US

Assignee:

AVEO PHARMACEUTICALS, INC. - Cambridge MA
OSI Pharmaceuticals, LLC - Farmingdale NY

International Classification:

A61K 31/517
A61P 35/00
C40B 30/04
A61K 31/4985

US Classification:

514249, 5142664, 506 9

Abstract:

The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.

US Patent:

61275212, Oct 3, 2000

Filed:

Jan 23, 1998

Appl. No.:

9/012515

Inventors:

Vivian Berlin - Dunstable MA
Maria Isabel Chiu - Boston MA
Guillaume Cottarel - West Roxbury MA
Veronique Damagnez - Cambridge MA

Assignee:

ARIAD Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07K 1900
C07K 1447
C07K 1100
C07K 1400
C12N 912

US Classification:

530350

Abstract:

The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.

US Patent:

61501379, Nov 21, 2000

Filed:

Dec 20, 1994

Appl. No.:

8/360144

Inventors:

Vivian Berlin - Dunstable MA
Maria Isabel Chiu - Boston MA
Guillaume Cottarel - West Roxbury MA
Veronique Damagnez - Cambridge MA

Assignee:

Ariad Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12N 1562
C12N 121
C12N 1512
C07H 2104

US Classification:

435 697

Abstract:

The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.